|Company Name:||Chengdu D-Innovation Pharmaceutical Co., Ltd. Gold|
||Product Name:(3b)-17-(3-pyridinyl)-Androsta-5,16-dien-3-ol;Abiraterone Acetate interMediate
Purity:99% HPLC Package:10g;50g;100g;500g;1kg;10kg;25kg
|Company Name:||Megchem Co., Ltd. Gold|
|Tel:||+86 (21) 5471-7132|
|Company Name:||Kaifute（Tianjin）Chemical Co., Ltd. Gold|
|Tel:||022-5865 9859 13820733852|
|Synonyms:||abiraterone;17-(3-Pyridyl)androsta-5,16-dien-3beta-ol;Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, (3beta)-;Cb 7598;Cb-7598;Unii-G819A456D0;Abiraterone(CB-7598);(3S,8R,9S,10R,13S,14S)-10,13-diMethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol|
|Product Categories:||API;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids;Inhibitor;Intermediate of Abiraterone Acetate;Inhibitors|
|Abiraterone Chemical Properties|
|Abiraterone Usage And Synthesis|
|Therapeutic agent for prostate cancer||Currently, for patients of advanced prostate cancer, androgen deprivation therapy including drugs and surgery is generally the preferred method of including drugs and surgery in order to reduce the testicular androgen synthesis. However, this treatment can’t suppress other parts of the body for yielding the male hormone. |
Abiraterone is a therapeutic agent for prostate cancer with the English name for Abiraterone. It has not yet been marketed in China. It is developed by researchers coming from the British Royal Marsden Hospital located in southwest (world-renowned cancer research treatment center). It is kind of drug which is able to repress any part of the body for androgen production. It can not only reduce the levels of the prostate-specific antigen (PSA) which represents the tumor activity, but also helps to shrink the tumor. It can also apply to cancer patients who have been subject to chemotherapy in the past, revealing treatment hope.
Previously, the patent of the Abiraterone was owned by British Cougar biopharmaceutical Company. But in 2009 Johnson Pharmaceutical acquire the Cougar Biological Company with $ 970 million, and thus getting the permission of the drug. The phase III clinical trial results have showed that the goods can significantly prolong patients with advanced prostate cancer including those who had used one or two docetaxel chemotherapy but still got deteriorating lives with a small drug side effects and good safety.
Abiraterone is an oral administrated cytochrome oxidase P450 (CYP450) c17 inhibitor which can decrease the androgen levels through inhibiting the key enzyme in the androgen synthesis--CYP450c17, and also has inhibitory effect on the androgens coming from testis and other body parts.
The above information is edited by the chemicalbook of Dai Xiongfeng.
|Chemical Properties||White Solid|
|Usage||Abiraterone, a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent pr
|Abiraterone Preparation Products And Raw materials|